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Abstract
Background: Patients with Hb E/b
0 thalassemia display remarkable variability in disease severity. To identify
genetic modifiers influencing disease severity, we conducted a two-stage genome scan in groups of 207 mild and
305 severe unrelated patients from Thailand with Hb E/b
0 thalassemia and normal a-globin genes.
Methods: First, we estimated and compared the allele frequencies of approximately 110,000 gene-based single
nucleotide polymorphisms (SNPs) in pooled DNAs from different severity groups. The 756 SNPs that showed
reproducible allelic differences at P < 0.02 by pooling were selected for individual genotyping.
Results: After adjustment for age, gender and geographic region, logistic regression models showed 50 SNPs
significantly associated with disease severity (P < 0.05) after Bonferroni adjustment for multiple testing. Forty-one
SNPs in a large LD block within the b-globin gene cluster had major alleles associated with severe disease. The
most significant was bthal_bg200 (odds ratio (OR) = 5.56, P = 2.6 × 10
-13). Seven SNPs in two distinct LD blocks
within a region centromeric to the b-globin gene cluster that contains many olfactory receptor genes were also
associated with disease severity; rs3886223 had the strongest association (OR = 3.03, P = 3.7 × 10
-11). Several
previously unreported SNPs were also significantly associated with disease severity.
Conclusions: These results suggest that there may be an additional regulatory region centromeric to the b-globin
gene cluster that affects disease severity by modulating fetal hemoglobin expression.
Background
b-Thalassemia is a genetic disease in which an abnormal
b-globin gene results in decreased (b+ thalassemia) or
completely absent (b
0 thalassemia) production of the
normal b-globin chain [1]. The hemoglobin E (HbE)
allele, point mutation (G®A) in codon 26 (Glu®Lys) of
the b-globin gene, can induce alternative splicing and
thus result in decreased b-globin E chains [2,3]. Homo-
zygosity for the HbE allele results in hypochromic
microcytosis and minimal anemia, but the compound
heterozygous condition, HbE/b
0 thalassemia causes a
surprisingly variable anemia, ranging from nearly
asymptomatic states to severe anemia and transfusion-
dependency [4-6]. Hb E/b
0 thalassemia is most prevalent
in and around Thailand, and with large numbers
affected in other countries in Southeast Asian [7].
Several disease modifying hematological parameters
have been identified, including fetal Hb (HbF), [8] red
blood cell count (RBCC), Hb, mean corpuscular volume
(MCV), mean corpuscular Hb (MCH), hemocrit, HbE,
[9] and genetic factors contributing to the variability of
some these parameters have been identified. HbF is the
primary modifier of disease severity, because it can com-
pensate for the lack of b-globin chains and HbA. There
are now three known HbF QTLs, accounting for ~50%
of the HbF heritability, Xmn1, HBS1L-MYB,a n d
BCL11A [10-15]. There are other QTLs that appear to
impact hematological parameters, including lymphotoxin
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monocyte chemotactic protein-1 (MCP-1), [16] and a
recent GWAS found SNPs on chromosomes 5 and 10
associated with MCV, SNPs on chromosomes 1, 4, 6,
and 20 associated with RBCC, and numerous SNPs in
the b-globin gene cluster and in erythrocyte membrane
protein band 4.1-like 2 associated with hematocrit, HgB,
MCH, MCV, and RBCC [17]. These QTLs for disease
severity are biologically plausible but require
confirmation.
Here, we attempt to identify variants that affect sever-
ity of HbE/b
0 thalassemia. An earlier study of SNPs in
five genes known to influence globin gene expression
and erythropoiesis failed to find significant associations
with disease severity [18]. Subsequently, we observed
strong association with 45 SNPs in a large linkage dise-
quilibrium (LD) block containing the b-globin gene
[19]. This association signal was ascribed to an effect of
the XmnI polymorphism. To expand the search for
severity modifying variants, we conducted a two-stage
(pooled genome wide genotyping followed by individual
genotyping in the top signals from stage one) associa-
tion study on a sample of Thai Hb E/b
0 thalassemia
patients.
Methods
Subjects
Sample collection, measurement of hematological data,
and categorization of patients in this study were
described elsewhere [18]. Briefly, a total of 1060 patients
with Hb E/b
0-thalassemia were ascertained from geo-
graphic regions across Thailand and a scoring system
based on seven clinical criteria [18] was used to classify
patients as mild (score = 0-3.5), moderate (score = 4-7)
or severe (score = 7.5-10). Table 1 lists the clinical cri-
teria and describes how they contribute to the severity
score. Patients with a clinically intermediate form of the
disease, detectable normal adult hemoglobin (HbA),
other b-o ra-globin mutation that known to affect dis-
ease severity such as (δb)
0-thalassemia or hereditary per-
sistence of fetal hemoglobin, or a-thalassemia were
excluded. Our analyses were based on the remaining
patients who were classified as mild (n = 207) or severe
(n = 305) disease. The study protocol was approved by
the Institutional Review Board of Mahidol University
and all subjects provided informed consent.
Hemoglobin Assays
Hemoglobin type and quantity were determined by
automated hemoglobin cation exchange chromatography
(Bio-Rad Variant, b-Thalassemia Short Program; Her-
cules, CA).
Stage 1: Pooled Genotyping
Initially, two regionally matched pools were created, one
representing participants with severe disease and another
containing those with mild disease. For the severe disease
pool, samples from individuals with the highest severity
scores, calculated using the scoring system, were prefer-
entially selected. The 395 unrelated samples were divided
to create one DNA pool representing cases with mild
symptoms (197 DNA samples) and one pool representing
severe symptom (198 DNA samples). DNA was amplified
with multiple displacement amplification (MDA) tech-
nology performed by Molecular Staging, Inc. (New
Haven, CT). MDA allows for uniform genome amplifica-
tion that results in minimal amplification bias across the
genome (data not shown). To create equimolar pools of
DNA, we used a stringent protocol for DNA concentra-
tion measurement using PicoGreen™ fluorescent dye in a
Fluoroskan Ascent™ fluorometer.
The pooled genotyping was conducted by Sequenom,
Inc. (San Diego, CA) using the MassARRAY platform. The
MassARRAY platform for SNP scoring was complemented
by a homogeneous, single-tube assay method (hME™ or
homogeneous MassEXTEND™) in which two oligonucleo-
tide primers anneal to and amplify a genomic target sur-
rounding the polymorphism. A third primer (EXTEND),
complementary to the amplified target up to but not
including the polymorphism, was enzymatically extended
o n eo raf e wb a s e st h r o u g ht h ep o l y m o r p h i cs i t eb ya
DNA polymerase and then terminated by sequence-deter-
mined incorporation of dideoxynucleotides. PCR and Mas-
sEXTEND reactions for all assays were performed on each
DNA pool. Organized in sets of 380 assays, two primer
plates were combined to perform a PCR with each DNA
pool. The PCR product plates were combined with the
EXTEND primers, and the extension reaction was
Table 1 Criteria and scoring system for classification of b
0-thalassemia/Hb E patients
Criteria Status Score Status Score Status Score
Hb at steady state, g/dL ≥7.5 0 6.0–7.5 1 <6 2
Age at onset, years >10 0 2–10 0.5 <2 1
Age at 1st transfusion, year >10 0 4–10 1 <4 2
Transfusion requirement Rare/none 0 Occasional 1 Regular 2
Spleen size, cm <3 0 3–10 1 >10 2
Splenectomy No 0 Yes 2
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four times onto a SpectroChip and measured with multi-
ple rasters with a mass spectrometer. The measurements
made on each chip were quantified using Sequenom’s
peak recognition and interpretation software. Areas under
the peaks were calculated using optimized algorithms, and
relative allele frequencies are estimated at 110,000 gene-
based SNPs. The assayed SNPs had a median spacing of
10.4 kilobases and covered approximately 99% of all
known and predicted human genes.
Stage 2: Verification and Individual Genotyping
SNPs with allele frequencies suggesting significant differ-
ences (P < 0.02) across pools and were selected for verifi-
cation by repeated pooled DNA analysis. This P-value
threshold was chosen to limit the number of SNPs for
individual genotyping and likewise the number of false
positive association signals and also to provide the number
of SNPs for individual genotyping specified in the study
design. At this threshold, 808 SNPs showed reproducible
allele frequency differences between disease severity pools
and were individually genotyped using the MassARRAY™
system (Sequenom, Inc., San Diego, CA). For quality con-
trol purposes, 29 subjects were genotyped twice and one
subject three times. Individuals and SNPs (N = 17) with
substantial missing data (< 90%) were not considered for
further analyses because these features usually indicate
poor DNA quality and problems with genotype calls,
respectively. Also, five X chromosomal SNPs with high
heterozygosity in males (>1%) and nine SNPs showing
inconsistencies in duplicated subjects or multiple Mende-
lian errors (>5%) were discarded for further analyses.
Twenty-one other SNPs were also excluded because they
had a low minor allele frequency, MAF, (<0.02 in both the
case and control samples). Since all subjects in our study
population have Hb E/b
0-thalassemia and tests for Hardy-
Weinberg equilibrium (HWE) in case-only populations are
subject to many caveats [20], SNPs with significant devia-
tion from HWE were not excluded. In total, 52 SNPs were
dropped, leaving 756 for analysis.
Statistical Analysis
The allele frequencies of the initial set of 110,000 SNPs
were compared between pools containing individuals
with mild disease vs. severe disease with Z tests with var-
iances adjusted for variation in source DNA quantitation,
diluting, and pipetting, as well as PCR/mass extension
and chip dispensing/mass spectrometry measurement.
The 756 individually genotyped SNPs which survived
quality control were tested for association with the dis-
ease severity classification variable and also with HbF%, a
quantitative measure known to affect disease severity.
Associations with the binary disease severity outcome
and HbF% were tested using logistic and linear regression
models, respectively, adjusted for gender, age, and geo-
graphic region. Since HbF% measurements are not valid
in regularly transfused patients, we only analyzed this
trait in the mild disease group, who are not regularly
transfused. The SNPs were modeled as the linear effect
of the number of minor alleles. To correct for multiple
testing, we employed a simple Bonferroni adjustment
based on the 765 SNPs that survived quality control and
were tested for association. We also computed a false dis-
covery rate (FDR) for each P-value [21]. We present both
the Bonferroni and FDR adjusted P-values to better illus-
trate the different levels of significance of the results. The
FDR is an accepted measure of the significance of multi-
ple association results, while we also state which findings
pass the overly conservative Bonferroni threshold to
highlight the highly significant findings. Finally, the link-
age disequilibrium (LD) structure of the SNPs on chro-
mosome 11, which included the b-globin gene cluster,
was analyzed using Haploview [22].
Results
The sample of 512 genotyped individuals was 51%
female and represented five geographical regions in
Thailand. Participants with mild disease were signifi-
cantly older than those with severe disease (P = 0.0002),
and males had significantly greater odds of severe dis-
ease than females (OR = 1.62, P = 0.01). The mean dis-
ease severity score was 2.1 among participants classified
as having mild disease and 8.4 in those with severe dis-
ease. The ratio of HbE to HbF increases in regularly
transfused patients, and likewise we observe a higher
HbE to HbF ratio in the severe disease group who
require more frequent transfusions. Table 2 shows the
Table 2 Characteristics of the study sample by disease
severity (N = 515)
Variable Mild Severe
Mean severity score (SD) 2.1 (1.0) 8.4 (0.8)
Mean Hb, g/dL (SD) 8.0 (1.4) 6.0 (1.1)
Mean HbF, % (SD) 40.7 (11.9) 31.1 (11.3)
Mean HbE, % (SD) 59.3 (11.9) 68.8 (11.3)
Mean HbE/HbF 1.8 2.7
Mean age, years (SD) 20 (14) 14 (9)
Female % 61 45
b-Thal Mutation, %
Codon 17 (A>T) 23 25
Codon 41/42 (-TTCT) 40 47
IVS II-654 (C>T) 9 10
Hb Khon Kaen 9 1
IVS I-5 (G>C) 4 7
Codon 71/72 (+A) 0.50 4
Beta Deletion 4 1
Other 11 5
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status, including demographic information and hemato-
logical measures. The mean age in the severe group was
lower than the mild group, mostly because severe
patients are identified at younger age. The difference in
severity between males and females has no known biolo-
gical explanation and likely represents random variation,
an issue which we correct by adjustment. It should be
noted that the hematological measures in the severe
group are skewed from their genetically determined
values because of the frequent transfusions in that
group. Thus, no further analyses of these measures were
performed in the severe group.
A total of 808 of the 110,000 SNPs showed reproduci-
ble allele frequency differences (P <0 . 0 2 )b e t w e e nt h e
samples of pooled DNA from mild and severe cases,
and these SNPs were genotyped in individual samples.
Fifty-two of the genotyped SNPs were excluded for
further analysis after quality control of the genotype
data. Prior to correction for multiple testing, 377 of the
756 analyzed SNPs showed evidence for association with
disease severity at P < 0.05, and 252 of these had a cor-
responding FDR = 5%. These included SNPs in the b-
globin gene cluster on chromosome 11 previously
reported to be associated with HbF levels in other sam-
ples, including the Xmn1 polymorphism 158 bp
upstream from the Gg gene and the HincII site in the
ψb-globin gene. Five of these SNPs were previously
reported to be associated with disease severity in this
sample by by Ma et al. [19] (see table 3). We observed
an association with rs4376364 HBS1L (P =4 . 3×1 0
-4),
although it was not significant after Bonferroni adjust-
ment. Table 3 shows the allele frequencies, locations,
and association results for the top 81 SNPs which had a
FDR = 1%. Of these 81 SNPs, 50 remained significant
after Bonferroni correction. LD analysis of the region on
chromosome 11 encompassing 52 of the SNPs listed in
table 3 revealed ten distinct haplotype blocks, the largest
spanning 56.5 Kb and containing most of the significant
SNPs (see Figure 1).
In addition to the previously reported associations
with SNPs in the b-globin cluster, we identified associa-
tion signals with seven SNPs in the region upstream
(centromeric) from the b-globin cluster that were not in
the same haplotype block. Rs3886223 was the most sig-
nificantly associated SNP in this group, with the com-
mon allele contributing to increased risk of severe
disease in an additive fashion (OR = 3.03, P =2 . 8 2×1 0
-8).
The association with this SNP remained significant after
adjustment for SNPs in the b-globin cluster, including
Xmn1, suggesting that the biological variant tagged by this
SNP is distinct from the one in the b-globin cluster. Xmn1
is correlated with rs3759074 at r
2 =. 9 2a n dw i t h
rs3886223 at r
2 = .46. This region contains many olfactory
receptor genes and rs3886223 is less than 500 bp upstream
from OR51B2.
Only one result among SNPs on other chromosomes
remained significant after Bonferroni adjustment;
rs6972505 (OR = 2.13, P =7 . 6×1 0
-6)i si na ni n t r o no f
solute carrier family 26 member 5 (SLC26A5) located on
chromosome 7. A second SNP, rs234915 in the GDP-
mannose 4,6-dehydratase gene (GMDS) on chromosome
6, was not significant after Bonferroni adjustment but
had a significant FDR (OR = 1.92, P =1 . 3×1 0
-4), with
the major allele associated with severe disease. Several
other SNPs had a FDR less than 0.01 (see Table 3).
Tests for genetic association with HbF% within the mild
disease group revealed nominally significant results with
14 SNPs in the b-globin gene cluster (Table 3).
Discussion
A previous study of a Hong Kong Chinese population
showed HbF to be 80-90% heritable, [12] and previous
studies have shown that Xmn1 accounts for approxi-
mately 13% of the variation in HbF in normal Europeans
[11] and for a similar proportion in a Chinese sample
heterozygous for the b-thalassemia mutation [12]. In
addition, about 15% of the HbF variance was explained
b yap o l y m o r p h i s mi nBCL11A on 2p15, 19% by an
intergenic variant in HBS1L-MYB on 6q23, and 10% by
Xmn1 in Europeans without hemoglobinopathies [10].
Assuming a maximum of 50% of the total trait variance
has been explained, a substantial number of QTL contri-
buting to the heritability of HbF remain undiscovered.
By studying a disease severity phenotype we have the
opportunity to identify variants that affect disease
through HbF as well as other pathways. In this study,
we replicated association findings from previous studies
of several disease-modifying SNPs in a Thai population
with Hb E/b
0 thalassemia and report associations with
SNPs that may represent additional b-globin gene regu-
latory regions or that alter disease severity through
novel pathways.
This study is the first whole genome association scan
for modifiers of Hb E/b
0 thalassemia. The two-stage
study design allowed for cost effective identification of a
targeted set of SNPs for individual genotyping. The fact
that most of the SNPs identified as having significant
differences in allele frequency between severity groups
in the analysis of pooled DNA samples also showed
nominally significant associations with severity after
individual genotyping demonstrates the utility of a two-
stage design.
Our study has several limitations. Since the pooled
genotyping was done on a marker panel that is less
d e n s et h a no n e su s e di nm a n yc o n t e m p o r a r yg e n o m e
wide association studies, we do not have the same level
of genome coverage provided by other genotyping
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Disease Severity HbF%
SNP Chr BP Gene Min Maj MAF OR P Bonf FDR Beta SE P Var
rs483850 1 203478366 FAIM3 T A 0.45 0.65 9.7E-04 7.3E-01 0.01 0.05 .05 0.10 .52
rs934956 2 104555647 Intergenic T C 0.17 1.93 5.6E-04 4.2E-01 0.01 0.00 .05 0.97 .40
rs370898 3 21442705 ZNF659 G T 0.05 0.37 1.4E-03 1 0.01 0.01 .05 0.93 .32
rs903047 3 132234707 NEK11 T C 0.35 1.58 1.5E-03 1 0.01 -0.03 .05 0.44 .30
rs6443662 3 180834067 Intergenic C T 0.29 0.58 3.8E-04 2.8E-01 0.005 0.02 .05 0.57 .30
rs950310 4 9519119 SLC2A9 A T 0.17 2.03 3.5E-04 2.6E-01 0.005 -0.08 .05 0.18 .29
rs258824 5 142577483 ARHGAP26 A G 0.39 1.58 1.1E-03 8.3E-01 0.01 -0.06 .05 0.12 .29
rs234915 6 2154576 GMDS A C 0.21 0.52 1.3E-04 9.5E-02 0.002 0.03 .05 0.45 .27
rs545537 6 117751734 ROS1 A G 0.17 1.90 8.4E-04 6.3E-01 0.01 0.03 .04 0.59 .27
rs4376364 6 135349178 HBS1L G T 0.34 1.70 4.3E-04 3.2E-01 0.01 -0.07 .05 0.10 .27
rs7804867 7 102627708 SLC26A5 A G 0.28 1.76 3.4E-04 2.6E-01 0.005 -0.03 .05 0.51 .27
rs6972505 7 102657988 SLC26A5 C G 0.24 2.13 7.6E-06 5.8E-03 0.0001 -0.04 .05 0.35 .27
rs1563408 7 113897140 FOXP2 G A 0.49 1.63 4.1E-04 3.1E-01 0.01 0.02 .05 0.52 .27
rs766003 9 69709994 c9orf135 G A 0.16 0.52 2.6E-04 1.9E-01 0.004 0.04 .05 0.37 .25
rs7936823 11 5206792 Intergenic C T 0.42 0.23 2.0E-11 1.5E-08 <.0001 0.10 .05 0.04 .25
rs6578588 11 5208867 Intergenic A G 0.42 0.21 1.2E-11 9.0E-09 <.0001 0.09 .05 0.07 .24
rs3813727 11 5212511 HBD T C 0.42 0.24 8.6E-11 6.5E-08 <.0001 0.10 .05 0.04 .23
rs3759074 11 5214371 Intergenic T C 0.41 0.18 3.6E-13 ± 2.7E-10 <.0001 0.10 .05 0.05 .23
rs10837643 11 5214635 Intergenic A T 0.43 0.22 5.4E-10 4.1E-07 <.0001 0.14 .05 0.002 .23
rs4320977 11 5214758 Intergenic T C 0.42 0.23 1.6E-11 1.2E-08 <.0001 0.10 .05 0.04 .22
rs3759073 11 5214862 Intergenic A G 0.42 0.22 2.5E-11 1.9E-08 <.0001 0.09 .05 0.07 .22
rs4402323 11 5215185 Intergenic G A 0.42 0.22 4.5E-12 3.4E-09 <.0001 0.10 .05 0.04 .22
rs4910543 11 5215423 Intergenic C G 0.42 0.22 5.8E-12 4.4E-09 <.0001 0.10 .05 0.04 .22
rs2105819 11 5216332 Intergenic C G 0.42 0.24 4.9E-11 3.7E-08 <.0001 0.11 .05 0.03 .22
rs10128556 11 5220248 HBBP1 A G 0.42 0.20 3.4E-13 2.6E-10 <.0001 0.10 .05 0.05 .21
rs2071348 11 5220725 HBBP1 C A 0.41 0.19 4.8E-13 3.6E-10 <.0001 0.09 .05 0.07 .21
rs11036431 11 5222255 HBBP1 T C 0.43 0.23 6.3E-12 4.8E-09 <.0001 0.08 .05 0.10 .20
rs916111 11 5225911 HBG1 A T 0.43 0.23 1.7E-11 1.3E-08 <.0001 0.10 .05 0.04 .20
rs2855038 11 5228721 HBG1 A G 0.43 0.24 4.5E-12 3.4E-09 <.0001 0.10 .05 0.04 .19
rs2855036 11 5229250 HBG2 A G 0.41 0.20 3.5E-13 2.6E-10 <.0001 0.09 .05 0.08 .19
rs2855126 11 5229721 HBG2 G C 0.43 0.24 7.0E-12 5.3E-09 <.0001 0.10 .05 0.03 .18
rs2855125 11 5230257 HBG2 A C 0.43 0.25 1.2E-11 8.8E-09 <.0001 0.12 .04 0.01 .18
rs2236794 11 5230843 HBG2 G A 0.42 0.24 2.5E-11 1.9E-08 <.0001 0.09 .05 0.07 .17
rs2070972 11 5231293 HBG2 T G 0.43 0.24 3.6E-12 2.7E-09 <.0001 0.10 .03 0.04 .16
rs2187608 11 5231423 HBG2 G C 0.41 0.20 7.0E-13 5.3E-10 <.0001 0.09 .04 0.06 .16
rs2070973 11 5231985 HBG2 A G 0.44 0.23 5.6E-12 4.2E-09 <.0001 0.09 .05 0.06 .16
rs7482144 (XmnI) 11 5232745 HBG2 T C 0.42 0.20 3.7E-13 2.8E-10 <.0001 0.07 .05 0.17 .15
rs2011051 11 5233395 HBG2 C A 0.43 0.24 1.2E-11 9.1E-09 <.0001 0.09 .05 0.07 .15
rs2855123 11 5233652 HBG2 T A 0.44 0.24 4.9E-11 3.7E-08 <.0001 0.07 .05 0.14 .14
rs2855121 11 5233869 HBG2 A G 0.41 0.20 2.2E-12 1.7E-09 <.0001 0.08 .05 0.12 .12
rs10160820 11 5239027 Intergenic G T 0.42 0.19 4.7E-13 3.6E-10 <.0001 0.09 .05 0.09 .12
rs7480802 11 5239080 Intergenic A G 0.43 0.24 2.1E-11 1.6E-08 <.0001 0.09 .05 0.07 .11
rs10160747 11 5240751 Intergenic A G 0.42 0.20 1.5E-12 1.2E-09 <.0001 0.09 .06 0.08 .11
rs10837707 11 5243234 HBE1 A G 0.43 0.22 1.4E-12 1.0E-09 <.0001 0.09 .05 0.07 .11
rs4910740 11 5243705 HBE1 C T 0.42 0.21 9.9E-13 7.5E-10 <.0001 0.10 .05 0.06 .11
bg200 * 11 5245549 HBE1 T G 0.41 0.18 2.6E-13 2.0E-10 <.0001 0.10 .04 0.07 .10
rs3834466 11 5247976 HBE1 C A 0.42 0.23 1.7E-11 1.2E-08 <.0001 0.07 .05 0.13 .10
rs3759070 11 5248038 HBE1 C G 0.41 0.21 1.5E-12 1.1E-09 <.0001 0.08 .04 0.09 .08
rs3759069 11 5248240 HBE1 T C 0.43 0.23 3.1E-12 2.4E-09 <.0001 0.09 .06 0.06 .08
rs11036562 11 5250549 HBE1 G T 0.48 0.38 2.7E-08 2.0E-05 <.0001 0.07 .05 0.12 .08
Sherva et al. BMC Medical Genetics 2010, 11:51
http://www.biomedcentral.com/1471-2350/11/51
Page 5 of 9platforms. While our use of a gene-based SNP panel
likely reduced the number of false negative results due
to low marker density, the fact that no SNPs were typed
in the BCL11A region, a well-confirmed modifier of
HbF level, [11-15] underscores the gain in information
afforded by the high density SNP arrays. In any case, the
low marker density does not negate the highly signifi-
cant associations we did identify, particularly those inde-
pendent of the b- g l o b i ng e n er e g i o n .T h eS N P s
allelotyped in the discovery phase are the set of marker
assays developed at Sequenom and demonstrated to be
polymorphic in Caucasians. Thus, prior to this study,
t h eM A F so ft h e s eS N P sw e r eu n k n o w ni nt h eT h a i
population. Similar to all GWA studies of non-Cauca-
sians using SNP chips developed based on marker allele
frequencies in Caucasians, some SNPs were not poly-
m o r p h i ca n dh e n c eat r u ea s s o c i a t i o ni nt h i sc i r c u m -
stance would not be detected.
The observation that several SNPs within the b-glo-
bin gene cluster were more significantly associated
Table 3: SNPs associated disease severity at FDR less than 0.02 (Continued)
rs11036634 11 5265154 Intergenic A G 0.50 2.34 1.4E-06 1.0E-03 <.0001 -0.02 .06 0.65 .07
bg12 * 11 5266933 Intergenic G T 0.49 2.31 6.8E-07 5.1E-04 <.0001 -0.06 .05 0.20 .06
rs11036639 11 5267001 Intergenic C T 0.46 0.34 6.0E-09 4.5E-06 <.0001 0.06 .04 0.21 .06
rs11036641 11 5267496 Intergenic A T 0.49 2.26 2.6E-06 2.0E-03 <.0001 -0.06 .04 0.21 .06
rs11036644 11 5268836 Intergenic C T 0.49 2.26 1.5E-06 1.2E-03 <.0001 -0.06 .05 0.18 .06
rs4601817 11 5268977 Intergenic G A 0.49 2.25 1.8E-06 1.4E-03 <.0001 -0.07 .05 0.17 .06
bg7 * 11 5270798 Intergenic G A 0.46 0.40 2.4E-07 1.8E-04 <.0001 0.05 .04 0.26 .06
rs7933082 11 5273186 Intergenic C G 0.48 0.47 1.5E-05 1.2E-02 0.0002 0.05 .04 0.36 .05
rs3888708 11 5274839 Intergenic T G 0.50 1.98 5.9E-05 4.5E-02 0.0009 -0.03 .04 0.47 .05
rs6578598 11 5275670 Intergenic T C 0.48 0.47 1.1E-05 8.4E-03 0.0002 0.04 .05 0.41 .05
rs10837774 11 5279964 OR51B4 A G 0.45 0.38 7.3E-08 5.5E-05 <.0001 0.05 .04 0.32 .04
rs3886223 11 5300323 OR51B2 T G 0.42 0.33 3.7E-11 ± 2.8E-08 <.0001 -0.01 .04 0.83 .04
rs2030090 11 5430669 OR51I2 G A 0.22 1.81 1.5E-03 1 0.01 0.04 .05 0.46 .04
rs449937 11 5446921 OR51A10P C T 0.16 2.08 5.2E-04 ± 3.9E-01 0.01 -0.03 .05 0.64 .03
rs366257 11 5447119 OR51A10P G A 0.16 2.21 2.3E-04 ± 1.7E-01 0.003 -0.03 .04 0.58 .03
rs446541 11 5448876 OR51A10P A T 0.26 0.48 2.5E-05 1.9E-02 0.0004 0.002 .07 0.96 .03
rs678343 11 64728207 CAPN1 G C 0.37 1.63 7.1E-04 ± 5.3E-01 0.01 0.04 .04 0.26 .03
rs593753 11 72369088 FCHSD2 T C 0.29 0.60 6.5E-04 ± 4.9E-01 0.01 0.05 .04 0.21 .02
rs638135 11 85863336 ME3 A G 0.23 0.59 1.1E-03 ± 8.3E-01 0.01 0.04 .06 0.32 .02
rs632538 11 85869341 ME3 G A 0.25 0.60 1.5E-03 ± 1 0.01 0.04 .06 0.35 .02
rs2580874 12 8650077 AICDA G A 0.20 0.54 4.5E-04 3.4E-01 0.01 0.09 .05 0.04 .02
rs1045411 13 29931232 HMGB1 A G 0.29 0.58 3.9E-04 2.9E-01 0.005 0.02 .05 0.70 .01
rs886599 14 70244197 Intergenic A G 0.10 2.70 1.2E-04 9.0E-02 0.002 0.04 .08 0.64 .01
rs1160027 17 51173101 Intergenic T G 0.20 0.56 8.5E-04 6.4E-01 0.01 -0.01 .06 0.79 .01
rs953695 18 59541550 SERPINB11 T G 0.21 1.83 7.6E-04 5.8E-01 0.01 -0.03 .04 0.63 .01
rs243341 19 4356106 CHAF1A T C 0.41 1.59 1.5E-03 1 0.01 -0.04 .04 0.33 .00
rs379327 19 61061978 NLRP4 A G 0.15 1.97 7.8E-04 5.9E-01 0.01 -0.07 .04 0.26 .00
rs639763 20 33325318 MMP24 T C 0.30 0.57 3.9E-04 2.9E-01 0.005 -0.04 .07 0.35 .00
rs6625978 X 71201690 PIN4 C A 0.06 3.35 1.3E-03 1 0.01 -0.001 .04 1.00 .00
BP = location of SNP in base pairs in NCBI build 36
Min = Minor allele
Maj = Major allele
Beta = Absolute change in HbF% on the log scale per copy of the minor allele
SE = Standard error of the Beta estimate
Bonf = Bonferroni adjusted P –value
FDR = false discovery rate
MAF = minor allele frequency
* = SNP not in NCBI database
± = Chromosome 11 SNPs associated with disease severity at P < 0.05 after adjustment for Xmn1
SNPs significantly associated with disease severity after Bonferroni correction are in bold
P-values for SNPs associated with HbF% at P ≤ 0.05 in the mild disease group are in bold
SNPs in italics were previously shown to be associated with disease severity in this sample by Ma et al. 2007 [19]
Var = Percent of the variation in log transformed HbF% explained by each SNP
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Page 6 of 9than Xmn1 with disease severity does not imply that
one of these variants rather than XmnI has a causal
effect on disease severity. There is a substantial body
of literature suggesting Xmn1h a saf u n c t i o n a lr o l ei n
determining HbF% and F-cell number [11,12,19] and
there is no such evidence for any of these other SNPs
Alternately, this observations may be due to Xmn1
allele frequency differences across populations. For
example, the frequency of the Xmn1 minor allele is
much higher in this sample (42%) than in most other
populations studied, including a sample of unaffected
Hong Kong Chinese parents of offspring with b-thalas-
semia (17%),[12] an unselected group of 720 UK twins
(33%),[10] the African American Cooperative Study of
Sickle Cell Disease (7%),[23] a Brazilian sickle cell dis-
ease study sample (0%),[23] and a group of 58 Chinese
b-thalassemia patients (5%) [24]. Although there are
small differences in significance among SNPs across
the b-globin gene cluster, all of these SNPs have simi-
lar minor allele frequencies and are highly correlated,
and it is not possible to identify definitively all causal
variants in the b-globin cluster by genetic association
analysis. Functional studies are needed to delineate the
spectrum of independent variants in the b-globin
region with a causal effect on disease severity and
HbF level.
The associations observed with SNPs in the olfactory
receptor cluster, which is adjacent to but distinct from
the b-globin cluster, are novel and may represent a
new disease modifying region. The biological connec-
tion between olfactory receptors, which interact with
odorant molecules in the nose to initiate a neuronal
response that triggers the perception of smell, and
severity of Hb E/b
0 thalassemia is not obvious. How-
ever, these SNPs (nearly all of which are located in
regulatory regions), or variants strongly associated with
them, may be acting as cis-regulatory elements [25]
and thus down-regulate transcription of HbF or impact
disease severity by altering expression of other b-glo-
bin genes. This hypothesis is consistent with the obser-
vation that at least one of these genes is expressed in
human erythroid cells at all stages of development
[26]. High-level transcription of the globin genes
through enhancement by a remote cis element, the
locus control region (LCR), may involve chromatin
remodeling [27] including the region containing the
olfactory receptor genes. As these findings are novel,
they have not been replicated in an independent sam-
ple. Replication of these associations for either disease
severity or HbF is necessary.
The findings with SNPs in SLC26A5 and GDMS are
also novel and need to be replicated in independent
Figure 1 Locations and linkage disequilibrium map structure of 70SNPs in the b-globin gene cluster and adjacent olfactory receptor
genes. The numbers in the squares represent the pairwise correlation (r
2) between SNPs and darker fill indicates higher r
2.
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Page 7 of 9samples. SLC26A5 acts as the primary motor molecule
in cochlear outer hair cells due to its ability to undergo
voltage-induced conformational change [28]. Although
no pathway through which this gene might affect thalas-
semia severity is immediately apparent, the SLC26A5
gene footprint partially overlaps the proteasome 26S
subumit gene (PSMC2), which immunoprecipitates with
transcription factors for RNA polymerase II in rats, indi-
cating a role in transcriptional regulation [29]. GDMS
has functions related to embryonic development and in
regulation of the immune response [30]. Finally, of note
there was only one individually typed SNP in the region
containing BCL11A,a n di tw a s3 0K bf r o mt h eg e n e .
T h eS N Pw a sr e m o v e dd u et ol o wc a l lr a t e ,b u ti tw a s
nominally associated with HbF% in the mild group (P =
0.01).
Conclusions
These results suggest that there may be an additional
regulatory region centromeric to the b-globin gene clus-
ter that affects disease severity by modulating fetal
hemoglobin expression. Also, the replication of previous
findings related to HbF highlight the utility of pooled
genotyping as a cost effective first step to identify a sub-
set of SNPs for individual genotyping.
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